Vascular endothelial growth factors: multitasking functionality in metabolism, health and disease

Journal of Inherited Metabolic Disease

Volumn 38, Issue 4, 2015, Pages 753-763

  Smith, Gina A ^a   Fearnley, Gareth W ^a   Harrison, Michael A ^a   Tomlinson, Darren C ^a   Wheatcroft, Stephen B ^b   Ponnambalam, Sreenivasan ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ATHEROSCLEROSIS; BINDING AFFINITY; CARDIOVASCULAR RISK; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHOLESTEROL METABOLISM; CHRONIC DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENDOTHELIUM CELL; FATTY ACID OXIDATION; GENE EXPRESSION; GLYCOLYSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; METABOLISM; NEOPLASM; NONHUMAN; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DISEASES; GENETICS; HEALTH; PHYSIOLOGY; VASCULAR DISEASE;

ANIMALS; DISEASE; HEALTH; HUMANS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84937200012     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-015-9838-4     Document Type: Review

References (105)

1. Al-Kateb H, Mirea L, Xie X et al (2007) Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe retinopathy in type 1 diabetes: the dcct/edic genetics study. Diabetes 56:2161–2168
2. Avraham-Davidi I, Ely Y, Pham VN et al (2012) ApoB-containing lipoproteins regulate angiogenesis by modulating expression of VEGF receptor 1. Nat Med 18:967–973
3. Awata T, Inoue K, Kurihara S et al (2002) A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51:1635–1639
4. Buraczynska M, Ksiazek P, Baranowicz-Gaszczyk I et al (2007) Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetes patients. Nephrol Dial Transplant 22:827–832
5. Cai J, Ahmad S, Jiang WG et al (2003) Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells. Diabetes 52:2959–2968
6. Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11:85–95
7. Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438:932–936
8. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298–307
9. Carmeliet P, Ferreira V, Breier G et al (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435–439
10. Carmeliet P, Moons L, Luttun A et al (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7:575–583
11. Carmeliet P, De Smet F, Loges S et al (2009) Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. Nat Rev Clin Oncol 6:315–326
12. Carmeliet P, Wong BW, De Bock K (2012) Treating diabetes by blocking a vascular growth factor. Cell Metab 16:553–555
13. Chiarelli F, Gaspari S, Marcovecchio ML (2009) Role of growth factors in diabetic kidney disease. Horm Metab Res 41:585–593
14. Churchill AJ, Carter JG, Ramsden C et al (2008) VEGF polymorphisms are associated with severity of diabetic retinopathy. Invest Ophthalmol Vis Sci 49:3611–3616
15. Coultas L, Chawengsaksophak K, Rossant J (2005) Endothelial cells and VEGF in vascular development. Nature 438:937–945
16. Cunningham SA, Arrate MP, Brock TA et al (1997) Interactions of Flt-1 and KDR with phospholipase C gamma: identification of the phosphotyrosine binding sites. Biochem Biophys Res Commun 240:635–639
17. Dagher Z, Ruderman N, Tornheim K et al (2001) Acute regulation of fatty acid oxidation and AMP-activated protein kinase in human umbilical vein endothelial cells. Circ Res 88:1276–1282
18. De Bock K, Georgiadou M, Carmeliet P (2013a) Role of endothelial cell metabolism in vessel sprouting. Cell Metab 18:634–647
19. De Bock K, Georgiadou M, Schoors S et al (2013b) Role of PFKFB3-driven glycolysis in vessel sprouting. Cell 154:651–663
20. De Saedeleer CJ, Copetti T, Porporato PE et al (2012) Lactate activates HIF-1 in oxidative but not in Warburg-phenotype human tumor cells. PLoS One 7:e46571
21. Devries C, Escobedo JA, Ueno H et al (1992) The Fms-like tyrosine kinase, a receptor for vascular endothelial growth-factor. Science 255:989–991
22. Eelen G, Cruys B, Welti J et al (2013) Control of vessel sprouting by genetic and metabolic determinants. Trends Endocrinol Metab 24:589–596
23. Elmasri H, Karaaslan C, Teper Y et al (2009) Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J 23:3865–3873
24. Errico M, Riccioni T, Iyer S et al (2004) Identification of placenta growth factor determinants for binding and activation of Flt-1 receptor. J Biol Chem 279:43929–43939
25. Fang L, Choi SH, Baek JS et al (2013) Control of angiogenesis by AIBP-mediated cholesterol efflux. Nature 498:118–122
26. Fearnley GW, Odell AF, Latham AM et al (2014) VEGF-A isoforms differentially regulate ATF-2-dependent VCAM-1 gene expression and endothelial-leukocyte interactions. Mol Biol Cell 25:2509–21
27. Feener EP, King GL (1997) Vascular dysfunction in diabetes mellitus. Lancet 350:SI9–SI13
28. Ferrara N (2010) Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol Biol Cell 21:687–690
29. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967–974
30. Ferrara N, Carver-Moore K, Chen H et al (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439–442
31. Fijalkowska I, Xu W, Comhair SA et al (2010) Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells. Am J Pathol 176:1130–1138
32. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS et al (2002) Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 51:3090–3094
33. Fontanella C, Ongaro E, Bolzonello S et al (2014) Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med 2:123
34. Fulton D, Gratton JP, McCabe TJ et al (1999) Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399:597–601
35. Giordano FJ, Gerber HP, Williams SP et al (2001) A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci USA 98:5780–5785
36. Grunewald FS, Prota AE, Giese A et al (2010) Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. Biochim Biophys Acta 1804:567–580
37. Hagberg CE, Falkevall A, Wang X et al (2010) Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 464:917–921
38. Han SW, Kim GW, Seo JS et al (2004) VEGF gene polymorphisms and susceptibility to rheumatoid arthritis. Rheumatology 43:1173–1177
39. Heissig B, Hattori K, Dias S et al (2002) Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109:625–637
40. Heitzer T, Schlinzig T, Krohn K et al (2001) Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104:2673–2678
41. Hiratsuka S, Maru Y, Okada A et al (2001) Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res 61:1207–1213
42. Holmqvist K, Cross M, Riley D et al (2003) The Shb adaptor protein causes Src-dependent cell spreading and activation of focal adhesion kinase in murine brain endothelial cells. Cell Signal 15:171–179
43. Hornig B, Arakawa N, Kohler C et al (1998) Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation 97:363–368
44. Jang C, Arany Z (2013) Metabolism: sweet enticements to move. Nature 500:409–411
45. Jin F, Hagemann N, Brockmeier U et al (2013) LDL attenuates VEGF-induced angiogenesis via mechanisms involving VEGFR2 internalization and degradation following endosome-trans-golgi network trafficking. Angiogenesis 16:625–637
46. Kawamoto A, Iwasaki H, Kusano K et al (2006) Cd34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells. Circulation 114:2163–2169
47. Kendall RL, Thomas KA (1993) Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90:10705–10709
48. Kendall RL, Rutledge RZ, Mao X et al (1999) Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues. J Biol Chem 274:6453–6460
49. Koch S, Claesson-Welsh L (2012) Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med 2:a006502
50. Koch S, Tugues S, Li X et al (2011) Signal transduction by vascular endothelial growth factor receptors. Biochem J 437:169–183
51. Lamalice L, Houle F, Huot J (2006) Phosphorylation of Tyr1214 within VEGFR-2 triggers the recruitment of Nck and activation of Fyn leading to SAPK2/p38 activation and endothelial cell migration in response to VEGF. J Biol Chem 281:34009–34020
52. Lee S, Chen TT, Barber CL et al (2007) Autocrine VEGF signaling is required for vascular homeostasis. Cell 130:691–703
53. Leopold JA, Walker J, Scribner AW et al (2003) Glucose-6-phosphate dehydrogenase modulates vascular endothelial growth factor-mediated angiogenesis. J Biol Chem 278:32100–32106
54. Li X, Tjwa M, Van Hove I et al (2008) Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol 28:1614–1620
55. Locasale JW, Cantley LC (2011) Metabolic flux and the regulation of mammalian cell growth. Cell Metab 14:443–451
56. Maher ER, Neumann HP, Richard S (2011) Von hippel-lindau disease: a clinical and scientific review. Eur J Hum Genet 19:617–623
57. Markowska AI, Jefferies KC, Panjwani N (2011) Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells. J Biol Chem 286:29913–29921
58. Matsumoto T, Bohman S, Dixelius J et al (2005) VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. EMBO J 24:2342–2353
59. Meadows KN, Bryant P, Pumiglia K (2001) Vascular endothelial growth factor induction of the angiogenic phenotype requires ras activation. J Biol Chem 276:49289–49298
60. Mittar S, Ulyatt C, Howell GJ et al (2009) VEGFR1 receptor tyrosine kinase localization to the Golgi apparatus is calcium-dependent. Exp Cell Res 315:877–889
61. Murohara T, Asahara T, Silver M et al (1998) Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 101:2567–2578
62. Nakagawa T (2007) Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol Renal Physiol 292:F1665–F1672
63. Olofsson B, Korpelainen E, Pepper MS et al (1998) Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 95:11709–11714
64. Orlic D, Kajstura J, Chimenti S et al (2001) Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 98:10344–10349
65. Paleolog EM (2002) Angiogenesis in rheumatoid arthritis. Arthritis Res 4:S81–S90
66. Pan S, World CJ, Kovacs CJ et al (2009) Glucose 6-phosphate dehydrogenase is regulated through c-Src-mediated tyrosine phosphorylation in endothelial cells. Arterioscler Thromb Vasc Biol 29:895–901
67. Rahimi N (2006) VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. Front Biosci 11:818–829
68. Raikwar NS, Liu KZ, Thomas CP (2013) Protein kinase C regulates Flt1 abundance and stimulates its cleavage in vascular endothelial cells with the release of a soluble PlGF/VEGF antagonist. Exp Cell Res 319:2578–2587
69. Ray D, Mishra M, Ralph S et al (2004) Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes 53:861–864
70. Reihill JA, Ewart MA, Salt IP (2011) The role of AMP-activated protein kinase in the functional effects of vascular endothelial growth factor-A and -B in human aortic endothelial cells. Vasc Cell 3:9
71. Robinson CJ, Stringer SE (2001) The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 114:853–865
72. Roskoski R Jr (2007) Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 62:179–213
73. Ruan GX, Kazlauskas A (2013) Lactate engages receptor tyrosine kinases Axl, Tie2, and vascular endothelial growth factor receptor 2 to activate phosphoinositide 3-kinase/Akt and promote angiogenesis. J Biol Chem 288:21161–21172
74. Ryu S, Lee JH, Kim SI (2006) IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes. Clin Rheumatol 25:16–20
75. Santos CR, Schulze A (2012) Lipid metabolism in cancer. FEBS J 279:2610–2623
76. Sasso FC, Torella D, Carbonara O et al (2005) Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. J Am Coll Cardiol 46:827–834
77. Sawamiphak S, Seidel S, Essmann CL et al (2010) Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 465:487–491
78. Sela S, Itin A, Natanson-Yaron S et al (2008) A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res 102:1566–1574
79. Shalaby F, Rossant J, Yamaguchi TP et al (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376:62–66
80. Sharma K, Sharma NK, Anand A (2014) Why amd is a disease of ageing and not of development: mechanisms and insights. Front Aging Neurosci 6:151
81. Shen L, Gao Y, Qian J et al (2011) A novel mechanism for endothelial progenitor cells homing: the SDF-1/CXCR4-rac pathway may regulate endothelial progenitor cells homing through cellular polarization. Med Hypotheses 76:256–258
82. Simons M (2005) Angiogenesis, arteriogenesis, and diabetes: paradigm reassessed? J Am Coll Cardiol 46:835–837
83. Suganthalakshmi B, Anand R, Kim R et al (2006) Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. Mol Vis 12:336–341
84. Sydorova M, Lee MS (2005) Vascular endothelial growth factor levels in vitreous and serum of patients with either proliferative diabetic retinopathy or proliferative vitreoretinopathy. Ophthalmic Res 37:188–190
85. Tammali R, Reddy AB, Srivastava SK et al (2011) Inhibition of aldose reductase prevents angiogenesis in vitro and in vivo. Angiogenesis 14:209–221
86. Tang JM, Wang JN, Zhang L et al (2011) VEGF/SDF-1 promotes cardiac stem cell mobilization and myocardial repair in the infarcted heart. Cardiovasc Res 91:402–411
87. Tang WH, Martin KA, Hwa J (2012) Aldose reductase, oxidative stress, and diabetic mellitus. Front Pharmacol 3:87
88. Tchaikovski V, Fellbrich G, Waltenberger J (2008) The molecular basis of VEGFR-1 signal transduction pathways in primary human monocytes. Arterioscler Thromb Vasc Biol 28:322–328
89. Tchaikovski V, Olieslagers S, Bohmer FD et al (2009) Diabetes mellitus activates signal transduction pathways resulting in vascular endothelial growth factor resistance of human monocytes. Circulation 120:150–159
90. Ulyatt C, Walker J, Ponnambalam S (2011) Hypoxia differentially regulates VEGFR1 and VEGFR2 levels and alters intracellular signaling and cell migration in endothelial cells. Biochem Biophys Res Commun 404:774–779
91. Urbanek K, Rota M, Cascapera S et al (2005) Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ Res 97:663–673
92. Uthra S, Raman R, Mukesh BN et al (2008) Association of VEGF gene polymorphisms with diabetic retinopathy in a south indian cohort. Ophthalmic Genet 29:11–15
93. Vaisman N, Gospodarowicz D, Neufeld G (1990) Characterization of the receptors for vascular endothelial growth factor. J Biol Chem 265:19461–19466
94. van der Meer P, De Boer RA, White HL et al (2005) The vegf +405 cc promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT-HF substudy. J Card Fail 11:279–284
95. Vizan P, Sanchez-Tena S, Alcarraz-Vizan G et al (2009) Characterization of the metabolic changes underlying growth factor angiogenic activation: identification of new potential therapeutic targets. Carcinogenesis 30:946–952
96. Waltenberger J (2009) VEGF resistance as a molecular basis to explain the angiogenesis paradox in diabetes mellitus. Biochem Soc Trans 37:1167–1170
97. Wang Y, Heilig KO, Minto AW et al (2010) Nephron-deficient Fvb mice develop rapidly progressive renal failure and heavy albuminuria involving excess glomerular GLUT1 and VEGF. Lab Invest 90:83–97
98. Warren CM, Ziyad S, Briot A et al (2014) A ligand-independent VEGFR2 signaling pathway limits angiogenic responses in diabetes. Sci Signal 7:ra1
99. Watson CJ, Webb NJ, Bottomley MJ et al (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12:1232–1235
100. Wei X, Schneider JG, Shenouda SM et al (2011) De novo lipogenesis maintains vascular homeostasis through endothelial nitric-oxide synthase (eNOS) palmitoylation. J Biol Chem 286:2933–2945
101. Werner GS, Richartz BM, Heinke S et al (2003) Impaired acute collateral recruitment as a possible mechanism for increased cardiac adverse events in patients with diabetes mellitus. Eur Heart J 24:1134–1142
102. Wiesmann C, Fuh G, Christinger HW et al (1997) Crystal structure at 1.7 a resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 91:695–704
103. Yeh WL, Lin CJ, Fu WM (2008) Enhancement of glucose transporter expression of brain endothelial cells by vascular endothelial growth factor derived from glioma exposed to hypoxia. Mol Pharmacol 73:170–177
104. Yu Y, Hulmes JD, Herley MT et al (2001) Direct identification of a major autophosphorylation site on vascular endothelial growth factor receptor Flt-1 that mediates phosphatidylinositol 3′-kinase binding. Biochem J 358:465–472
105. Zeiher AM, Drexler H, Saurbier B et al (1993) Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 92:652–662